0001179110-20-000559.txt : 20200114 0001179110-20-000559.hdr.sgml : 20200114 20200114180905 ACCESSION NUMBER: 0001179110-20-000559 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200107 FILED AS OF DATE: 20200114 DATE AS OF CHANGE: 20200114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fletcher Robert C. CENTRAL INDEX KEY: 0001508231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 20526930 MAIL ADDRESS: STREET 1: 730 STOCKTON DRIVE CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 4843481600 MAIL ADDRESS: STREET 1: 505 EAGLEVIEW BOULEVARD STREET 2: SUITE 212 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 4/A 1 edgar.xml FORM 4/A - X0306 4/A 2020-01-07 2020-01-10 0 0000861838 IDERA PHARMACEUTICALS, INC. IDRA 0001508231 Fletcher Robert C. C/O IDERA PHARMACEUTICALS, INC. 505 EAGLEVIEW BLVD., SUITE 212 EXTON PA 19341 0 1 0 0 Sr. VP, Bus. Dev. & Strategy Common Stock 2020-01-07 2020-01-08 4 S 0 1615 1.7804 D 16485 D The Form 4 filed on January 10, 2020 did not include the Deemed Execution Date in Column 2A and corresponding footnote disclosure. This amendment to the Form 4 is being filed to include this information for the reported transaction. In accordance with terms of the RSU agreement, the "sell to cover" provision is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act. Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Of the reported shares, 13,575 shares are represented by unvested RSUs. /s/ Robert Clayton Fletcher 2020-01-14